Abstract Body

Background

Cabotegravir + rilpivirine long-acting (CAB+RPV LA) is the only complete LA regimen approved for treatment-experienced people with HIV with viral loads (VL) <50 copies/mL (c/mL). This analysis described demographics, clinical characteristics, and virologic outcomes in individuals on CAB+RPV LA stratified by VL at initiation.

Methods

Treatment-experienced adults who initiated CAB+RPV LA from 21JAN2021-31DEC2024 in OPERA were stratified into 2 groups (VL <50 c/mL and VL ≥50 c/mL at initiation). Virologic outcomes were assessed among those who received initiation injections ≤67 days apart and had ≥1 VL through 28FEB2025. In the VL <50 c/mL group, suppression was maintained if all or the last follow up VL was <50 c/mL. CVF was defined as 2 consecutive VLs ≥200 c/mL, or 1 VL ≥200 c/mL followed by discontinuation. In the VL ≥50 c/mL group, suppression was achieved if any or the last VL was <50 c/mL; CVF was assessed after suppression to <50 c/mL.

Results

Among 5,264 adults receiving CAB+RPV LA, 4,587 (87%) had a VL <50 c/mL, 582 (11%) had a VL ≥50 c/mL, and 95 (2%) were missing VL at initiation. Demographics at initiation differed substantially across VL groups (table). Over half received all injections on-time (VL <50 c/mL: 58%, VL ≥50 c/mL: 56%), with a median of 1 delayed injection (IQR: 1, 2). 1,466 individuals had short delays (68-97 days after preceding injection; median delay: 3 days late [IQR: 2, 9]). 397 individuals had long delays (98-127 days after preceding injection; median delay: 52 days late [IQR: 45, 56]). A majority remained on CAB+RPV LA at last follow up (VL <50 c/mL: 78%,VL ≥50 c/mL: 73%), with median follow-up 16 and 15 months respectively. In the VL <50 c/mL group, 95% maintained suppression at last follow up and 81% were suppressed at all follow up VLs. Most (87%) of the VL ≥50 c/mL group achieved suppression to <50 c/mL; 79% remained suppressed at last follow up. CVF was rare (1-2%) in both groups.

Conclusions

Individuals initiating CAB+RPV LA with VL ≥50 c/mL (off-label use) achieved outcomes similar to those initiating with VL <50 c/mL. Most individuals in the VL <50 c/mL group maintained suppression; the majority in the VL ≥50 c/mL group achieved suppression, with many remaining suppressed at last follow up. CVF was rare across this large real-world population regardless of VL at initiation. These findings reinforce CAB+RPV LA as a versatile and effective therapy for a diverse population, including those struggling with adherence or tolerability to oral regimens.

Table or Figure